

# AMCoR

Asahikawa Medical University Repository <http://amcor.asahikawa-med.ac.jp/>

Investigative Ophthalmology and Visual Science (2015.11) 56(12):7551-7559.

Role of Glial Cells in Regulating Retinal Blood Flow During Flicker-Induced Hyperemia in Cats.

Youngseok Song, Taiji Nagaoka, Takafumi Yoshioka, Seigo Nakabayashi, Tomofumi Tani, Akitoshi Yoshida

1 **Role of Glial Cells in Regulating Retinal Blood Flow during Flicker-Induced**  
2 **Hyperemia in Cats**

3

4 *Youngseok Song, Taiji Nagaoka,\* Takafumi Yoshioka, Seigo Nakabayashi,*  
5 *Tomofumi Tani, and Akitoshi Yoshida*

6

7 From the Department of Ophthalmology, Asahikawa Medical University, Asahikawa,  
8 Japan.

9

10 **Running title: Glial Cell Role in Retinal Blood Flow**

11

12 Corresponding author: Taiji Nagaoka, MD, PhD, Department of Ophthalmology,  
13 Asahikawa Medical University, Midorigaoka Higashi 2-1-1-1, Asahikawa, 078-8510,  
14 Japan; phone: +81-166-68-2543; fax: +81-166-68-2549;  
15 E-mail: nagaoka@asahikawa-med.ac.jp.

16

17 Supported by a Grant-in-Aid for Scientific Research (B) 25293352 and  
18 Challenging Exploratory Research 25670724 from the Ministry of Education, Science,  
19 and Culture, Tokyo, Japan (to TN) and a Grant-in-Aid for Scientific Research (B)  
20 26861430 from the Ministry of Education, Science, and Culture, Tokyo, Japan (to YS)

21

22 **Word count: 4,259 words**

23 The authors have no financial/conflicting interests to disclose.

24

25 **ABSTRACT**

26 **PURPOSE.** To investigate how glial cells participate in retinal circulation during flicker  
27 stimulation in cats.

28 **METHODS.** Using laser Doppler velocimetry, we measured the vessel diameter and  
29 blood velocity simultaneously and calculated the retinal blood flow (RBF) in feline  
30 first-order retinal arterioles. Twenty-four hours after intravitreal injections of  
31 L-2-aminoadipic acid (LAA), a gliotoxic compound, and the solvent of 0.01 N  
32 hydrochloric acid as a control, we examined the changes in RBF in response to 16-Hz  
33 flicker stimulation for 3 minutes. We also measured the changes in RBF 2 hours after  
34 intravitreal injection of N $\omega$ -propyl-L-arginine (L-NPA), a selective neuronal nitric  
35 oxide synthase inhibitor, in LAA-treated eyes. To evaluate the effects of LAA on retinal  
36 neuronal function, electroretinograms (ERGs) were monitored. Immunohistochemical  
37 examinations were performed.

38 **RESULTS.** In LAA-treated eyes, histologic changes selectively occurred in retinal glial  
39 cells. There were no significant reductions in amplitude or elongation of implicit time in  
40 ERG after LAA injections compared with controls. In control eyes, the RBF gradually  
41 increased and reached the maximal level ( $53.5 \pm 2.5\%$  increase from baseline) after 2 to  
42 3 minutes of flicker stimulation. In LAA-treated eyes, the increases in RBF during  
43 flicker stimulation were attenuated significantly compared with controls. In  
44 LAA-treated eyes 2 hours after injection of L-NPA, flicker-evoked increases in RBF  
45 decreased significantly compared with LAA-treated eyes.

46 **CONCLUSIONS.** The current results suggested that increases in RBF in response to  
47 flicker stimulation were regulated partly by retinal glial cells.

48

49 **Keywords.**

50 retinal blood flow, flicker induced hyperemia, retinal glial cells, gliotoxic compound,

51 neurovascular coupling

52

53 **Précis**

54 The reduction in the flicker-evoked increase in retinal circulation after intravitreal

55 injection of gliotoxic compound in cats suggests that retinal glial cells are involved in the

56 regulation of the retinal circulation during flicker stimulation.

57

58 To maintain neuronal function, the brain has evolved neurovascular coupling  
59 mechanisms to increase the regional blood flow, which Roy and Sherrington referred to  
60 as functional hyperemia, when they first described this concept more than a century  
61 ago.<sup>1,2</sup> Retinal vessels dilate and retinal blood flow (RBF) increases as a result of the  
62 functional hyperemic response when the retina is stimulated by a flickering light,  
63 indicating that the retinal neural activity is associated with blood flow and metabolism,  
64 and considered as metabolic autoregulation in the retinal circulation.<sup>3,4</sup>

65 Metabolic autoregulation in neurovascular coupling is maintained by three major  
66 cells, i.e., neurons, vasculature, and glial cells, in the brain and the retina.<sup>2,5,6</sup> Glial cells,  
67 including Müller cells and astrocytes as the main glial cells in the retina,<sup>7</sup> are vital for  
68 maintaining normal retinal function.<sup>8</sup> Recent evidence from an animal experiment  
69 indicates that glial cells play a principal role in coupling neuronal activity to vessel  
70 dilation in retinal functional hyperemia.<sup>6</sup> Indeed, impaired glial cell activity may be  
71 related to the pathological mechanisms of ocular disorders such as diabetic retinopathy  
72 (DR) and glaucoma.<sup>9-12</sup> Moreover, some clinical studies have reported that vasodilation  
73 of the retinal vessels elicited by flicker stimuli deteriorates in patients with these  
74 diseases.<sup>13-15</sup> However, the involvement of glial cells in regulating the RBF in response  
75 to flicker stimulation has not been well determined.<sup>16</sup> Although some reports have  
76 focused on the role of glial cells in metabolic autoregulation in neurovascular  
77 coupling,<sup>2,6,16-18</sup> the role in the retinal vasculature remains unclear.

78 In previous studies, L-2-amino adipic acid (LAA),<sup>17,19,20</sup> a gliotoxic compound,  
79 was injected intravitreally to examine the specific role of glial cells in the retina. We  
80 investigated the role of retinal glial cells in regulating the RBF in response to flicker

81 stimulation after suppressing the retinal glial cell function with intravitreal injection of  
82 LAA in cats.

83

## 84 **MATERIALS AND METHODS**

### 85 **Animal Preparation**

86 The Animal Care Committee of Asahikawa Medical University approved the study  
87 protocols in cats; the study adhered to the ARVO Statement for the Use of Animals in  
88 Ophthalmic and Vision Research. Thirty-six adult cats (2.6-3.2 kg) of either sex were  
89 tracheostomized and mechanically ventilated with room air containing 2% sevoflurane.  
90 The flow rate of sevoflurane was maintained at 1.5 L/minute during the experiment.  
91 Catheters were placed in the femoral arteries and vein. The mean arterial blood pressure  
92 (MABP) and heart rate (HR) were monitored continuously with a transducer (PowerLab,  
93 ADInstruments, Inc., Colorado Springs, CO) and recorder (LabChart, ADInstruments  
94 Inc.) in the proximal thoracic descending aorta. Pancuronium bromide (0.1 mg/kg/h)  
95 (Daiichi Sankyo Co., Tokyo, Japan) was infused continuously via the femoral vein to  
96 maintain skeletal muscle relaxation. With the animal prone, the head was fixed in a  
97 stereotaxic instrument. The arterial pH (pH), arterial partial carbon dioxide tension  
98 ( $\text{PaCO}_2$ ), arterial partial oxygen tension ( $\text{PaO}_2$ ), and bicarbonate ion ( $\text{HCO}_3^-$ ) were  
99 measured intermittently with a blood gas analyzer (model ABL5, Radiometer,  
100 Copenhagen, Denmark). The rectal temperature was measured and maintained between  
101  $37^\circ$  and  $38^\circ$  C with a heated blanket. The pupils were dilated with 0.4% tropicamide  
102 (Santen Pharmaceutical Co., Osaka, Japan). A 0-diopter contact lens (Seed Co. Ltd.,  
103 Tokyo, Japan) was placed on the cornea, which was protected by instillation of a drop  
104 of sodium hyaluronate (Healon, Abbott Medical Optics, Inc., Abbott Park, IL). A

105 26-gauge butterfly needle was inserted into the anterior chamber and connected to a  
106 pressure transducer and a balanced salt solution (Alcon, Fort Worth, TX) reservoir for  
107 monitoring and maintaining the intraocular pressure (IOP) at a constant level of 10  
108 mmHg, respectively. Table 1 shows the systemic and ocular parameters at rest.

### 109 **RBF Measurements**

110 A laser Doppler velocimetry (LDV) system (Laser Blood Flowmeter, model 100, Canon,  
111 Inc., Tokyo, Japan) customized for feline use was used to measure the retinal arteriolar  
112 diameter (D) (in micrometers) and velocity (V) (millimeters/second) as described  
113 previously.<sup>21,22</sup> The RBF in the arterioles (microliters/minute) was calculated based on  
114 the acquired V and D. Laser Doppler measurements of the temporal retinal arterioles  
115 were performed in one eye of each animal. The first-order arterioles were chosen for  
116 study because they have relatively straight segments and were sufficiently distant from  
117 the adjacent vessels for consistent measurements.

118 The RBF was calculated using the formula  $RBF = S \times V_{\text{mean}}$ , where S is the  
119 cross-sectional area of the retinal arteriole at the laser Doppler measurement site,  
120 assuming a circular cross-section, and  $V_{\text{mean}}$  is the mean blood V calculated as  $V_{\text{mean}}$   
121  $= V_{\text{max}}/2$ .<sup>23</sup> The MABP was determined using the formula  $MABP = \text{diastolic BP} +$   
122  $(\text{systolic BP} - \text{diastolic BP})/3$ , which is the index of the systemic BP. Because the cats  
123 were prone during the experiments, the ocular perfusion pressure (OPP) was calculated  
124 as  $OPP = MABP - IOP$ .<sup>24,25</sup>

### 125 **Flicker Stimulation**

126 As we showed previously,<sup>26</sup> we used 16-Hz stimuli as flicker stimulation because the  
127 frequency obtained a maximal RBF response in cats and the eyes were allowed to  
128 dark-adapt for 2 hours before flicker stimuli.<sup>26</sup> Fundus illumination was used only for

129 alignment before dark adaptation started. The detailed protocol and instruments used in  
130 flicker stimulation were described previously.<sup>26</sup>

### 131 **Intravitreal Injections and Chemicals**

132 A 30-gauge needle (100- $\mu$ L syringe; Hamilton, Reno, NV) was used for the intravitreal  
133 injections (3 mm posterior to the limbus) with care taken not to injure the lens and  
134 retina.<sup>21</sup> The head of the needle was positioned over the optic disc region. LAA and  
135 bradykinin (BK) were purchased from Sigma Chemical Co. (St. Louis, MO).  
136 N $\omega$ -propyl-L-arginine (L-NPA) was obtained from Cayman Chemicals Co. (Ann  
137 Arbor, MI). The drugs without LAA were dissolved in phosphate buffered saline (PBS).  
138 LAA was dissolved in 0.01 N hydrochloric acid (HCl) because LAA does not dissolve  
139 in PBS. The volume of the intravitreal injections was 50  $\mu$ l, which does not alter retinal  
140 circulatory parameters and minimizes the systemic effects of the inhibitors.<sup>21</sup> Because  
141 the cat vitreous is about 2.5 mL, the 50- $\mu$ l solution injected into the vitreous cavity is  
142 diluted by a factor of 50 near the retinal vessels. Hereafter, we refer to drug  
143 concentrations as injected concentrations.

144 The 20 and 60 mM LAA concentrations (final concentrations in the vitreous  
145 cavity of 0.4 and 1.2 mM, respectively) were chosen because 1.25 mM L-2-aminoadipic  
146 acid causes swelling of the Müller cells and astrocytes while the remaining neural cells  
147 remain intact.<sup>27</sup> The 24-hour time course after intravitreal injection of LAA was chosen  
148 because pathologic changes and dysfunction on the electroretinograms (ERGs) were not  
149 observed in the neural retina, although the Müller cells had some damage, i.e., pale  
150 stained nuclei and increased glycogen granules 24 hours after the LAA injections.<sup>17,27</sup>

### 151 **Changes in RBF to Flicker Stimulation**



152 The measurements of D and V were started 5 minutes before flicker stimulation. The  
153 mean of five measurements at 1-minute intervals was recorded as the baseline value.  
154 The retina then was stimulated by the flickering light and the RBF measurements were  
155 performed every 30 seconds during the stimulation period. The changes in the retinal  
156 circulatory parameters were expressed as the percent change from baseline. In the  
157 current study, because the blood flow reaches a plateau 2 minutes after flicker  
158 stimulation, in the current study, we expressed the average value of three points of 120  
159 to 180 seconds as the maximal change.<sup>26</sup> To assess whether LAA suppresses  
160 flicker-induced hyperemia in the retinal arterioles, we evaluated the changes in the RBF  
161 in response to flicker stimuli 24 hours after intravitreal injections of LAA or 0.01 N HCl  
162 as a control.

### 163 **Effects of Gliotoxic Compound on Increased RBF in Response to BK**

164 Because we confirmed previously that BK causes endothelium-dependent, nitric oxide  
165 (NO)-mediated vasodilation in isolated porcine retinal arterioles,<sup>28</sup> we injected BK into  
166 the vitreous to cause the endothelium-dependent vasodilation.<sup>29</sup> The increase in RBF  
167 induced by intravitreal injections of BK (50  $\mu$ M) reached the maximal level at 120  
168 minutes and persisted for at least 3 hours in our previous study.<sup>29</sup> These concentrations  
169 were sufficient for the maximal vasodilation concentrations of BK, based on our  
170 previous in vitro study.<sup>28</sup>

171 To assess the effect of LAA on endothelial vasodilatory function in the changes in  
172 the RBF in response to intravitreal injection of BK, the RBF was measured before and 2  
173 hours after intravitreal injection of BK with pre-treatment with LAA (20 mM, 60 mM)  
174 or 0.01 N HCl as a vehicle.

**175 Changes in Basal Retinal Arterial Blood Flow before and after Intravitreal****176 Injection of the Gliotoxic Compound**

177 To determine the effect of the gliotoxic compound on basal retinal circulation, we  
178 measured the basal RBF before and 24 hours after intravitreal injection of a 60-mM  
179 concentration of LAA (n=4) in the same animals.

**180 Effects of a nNOS Inhibitor in LAA-treated eyes**

181 We showed previously that increases in RBF during flicker stimulation were attenuated  
182 after intravitreal injection of L-NPA (5 mM), a selective neuronal NO synthase (nNOS)  
183 inhibitor,<sup>26</sup> suggesting that nNOS contributes to regulation of the retinal circulation  
184 during flicker stimulation. To determine whether the decrease in RBF in response to  
185 flicker stimulation in LAA (60 mM)-treated eyes resulted from reduced NO by nNOS in  
186 retinal glial cells, we measured the RBF in response to flicker stimulation in LAA (60  
187 mM)-treated eyes 2 hours after intravitreal L-NPA injection (5 mM). L-NPA was  
188 injected 22 hours after LAA to confirm the maximal responses of LAA and L-NPA.

**189 Immunohistochemistry**

190 For whole-mount assessment, the eyes were enucleated and fixed in 1%  
191 paraformaldehyde for 1 hour. The retina was blocked and permeabilized in 5% goat  
192 serum with 0.3% Triton (Wako Pure Chemical Industries, Ltd., Osaka, Japan) in PBS  
193 for 1 to 2 hours. The retinas were transferred to primary antibodies diluted in block  
194 solution and incubated for 1 hour at room temperature. The primary antibody was  
195 mouse anti-glial fibrillary acidic protein (GFAP)-cy3 antibody (1:400; Sigma-Aldrich,  
196 St. Louis, MO) and isolectin IB4 conjugated to Alexa Fluor 647 (1:200) (Invitrogen,  
197 Carlsbad, CA) was stained. Ok as changed? The slides were mounted (Dako, Tokyo,  
198 Japan) and observed for green (cy3) and red (Alexa Fluor 647) staining and analyzed

199 with a fluorescence microscope (Fluoview FV 1000, Olympus, Tokyo, Japan).  
200 Photoshop CS 6 (Adobe Systems, Inc., Tokyo) was used to quantify the GFAP  
201 expression. The mean densities of three sites ( $300 \times 300 \mu\text{m}$ ) for each group were  
202 selected randomly in the observed area about 3 mm superior to the center of the optic  
203 nerve head (ONH) and measured, and the averages were compared.

#### 204 **Histologic Examination**

205 To determine the gliotoxic effects of LAA, histologic examinations were performed 24  
206 hours after intravitreal injection of LAA 60 mM or 0.01N HCl. The enucleated eyes  
207 were fixed in 2% paraformaldehyde-2.5% glutaraldehyde in 10 mM PBS for 3 hours,  
208 then fixed in 4% paraformaldehyde, and embedded in paraffin. A transverse section of  
209 each retina ( $5 \mu\text{m}$ ) was cut parallel to the medullary rays of the ONH. The section of the  
210 retina was stained with hematoxylin and eosin (HE) and examined by light microscopy.  
211 To evaluate the retinal neural damage, the thicknesses of the ganglion cell layer (GCL),  
212 inner nuclear layer (INL), and outer nuclear layer (ONL) were measured in transverse  
213 sections. For this analysis, three light photomicrographs (magnification,  $\times 400$ ) were  
214 taken in a masked fashion about 3 mm superior to the center of the ONH. The thickness  
215 of each layer was averaged for each eye to obtain data for statistical analysis.

#### 216 **ERG Recording and Analysis**

217 To determine the selective gliotoxicity of LAA on the retinal function, ERGs were  
218 performed before and 24 hours after intravitreal injection of LAA (60 mM) or 0.01 N  
219 HCl as a solvent. A light-emitting diode light stimulator (LS-C, Mayo Corporation,  
220 Aichi, Japan) and Ganzfeld Dome, a data acquisition system, and AC amplifier (PuREC  
221 system, PC-100, Mayo Corporation) were used to record the ERGs. Before the ERG  
222 recordings, the cats were dark-adapted for 2 hours after mydriasis with 0.4%

223 tropicamide (Santen Pharmaceutical Co.). The ERG was performed under general  
224 anesthesia induced by sevoflurane; recordings were performed with a gold ring active  
225 electrode on the cornea, a gold dish negative electrode in the mouth, and the ground  
226 electrode on an earlobe by single flash stimulation. The flash stimulus intensity was 1.0  
227 cds/m<sup>2</sup>. Bandpass filters were set at 0.3 to 500 Hz and the amplifier gain was set at  
228 x10,000 for the a- and b-waves. The amplitudes and the implicit times of the a- and  
229 b-waves were measured. All waveforms were analyzed by the PuREC system. We  
230 performed ERGs before and 24 hours after intravitreal injection of LAA at 60 mM  
231 (n=7) or 0.01 N HCl (n=7) as a control, and the amplitudes and the implicit times of the  
232 a- and b-waves of LAA-treated eyes were compared with those of the controls.

### 233 **Statistical Analysis**

234 All data are expressed as the mean percentage  $\pm$  standard error of the mean. The  
235 vasodilator responses were calculated as the percentage increases of the RBF from  
236 baseline. For statistical analysis, we used analysis of variance (ANOVA) for repeated  
237 measurements, followed by post hoc comparison with the Dunnett procedure. Group  
238 comparisons of the RBF, histologic examinations, and ERGs were performed using the  
239 Mann-Whitney U-test or Wilcoxon signed-rank test.  $P < 0.05$  was considered  
240 statistically significant.

241

## 242 **RESULTS**

### 243 **Effects of Gliotoxic Compound on RBF at Baseline and in Response to Intravitreal** 244 **Injection of BK**

245 Twenty-four hours after injection of LAA (60 mM), there were no significant  
246 changes in retinal (D, V, RBF) and systemic circulatory (pH, PaCO<sub>2</sub>, PaO<sub>2</sub>, HCO<sub>3</sub><sup>-</sup>,

247 MABP, or HR) parameters (n=6) (Table 2) or in the amplitude or elongation of the  
248 implicit time of the ERG a- and b-waves (n=7) (Table 3).

249 In the 20- and 60-mM LAA groups, increases in D, V, and RBF induced by  
250 intravitreal injection of BK were comparable to those in the control groups (Fig. 1).  
251 There were no significant changes in any systemic circulatory parameters (pH,  
252 PaCO<sub>2</sub>, PaO<sub>2</sub>, HCO<sub>3</sub><sup>-</sup>, MABP, or HR) before and 120 minutes after intravitreal  
253 injection of BK (data not shown).

#### 254 **Effects of Gliotoxic Compound on RBF in Response to Flicker Stimulation**

255 After 3 minutes of 16-Hz flicker stimulation, the D, V, and RBF maximally increased by  
256  $5.9 \pm 1.2\%$ ,  $36.9 \pm 2.1\%$ , and  $53.5 \pm 2.5\%$ , respectively, in the control group. In the  
257 LAA groups, those changes were significantly lower; the D, V, and RBF maximally  
258 increased by  $4.5 \pm 1.0\%$ ,  $25.4 \pm 3.5\%$ , and  $37.1 \pm 5.4\%$ , respectively, in the 20-mM  
259 LAA group maximally increased by  $2.8 \pm 0.8\%$ ,  $12.1 \pm 3.3\%$ , and  $19.6 \pm 2.4\%$ ,  
260 respectively, in the 60-mM LAA group (Fig. 2). There were no significant changes in  
261 any systemic parameters (pH, PaCO<sub>2</sub>, PaO<sub>2</sub>, HCO<sub>3</sub><sup>-</sup>, MABP, or HR) before, during, and  
262 after flicker stimulation (data not shown). In the preliminary study, we confirmed the  
263 absence of significant differences in the increases in the RBF in response to the flicker  
264 stimuli between the 0.01 N HCl- and PBS-treated eyes (data not shown).

#### 265 **Effects of nNOS Inhibitor L-NPA on Flicker-Evoked Increase in Retinal**

##### 266 **Circulation in LAA-Treated Eyes**

267 In LAA-treated eyes, intravitreal injection of L-NPA (5 mM) significantly reduced the  
268 flicker-induced increases in RBF compared with eyes treated with only LAA (Fig. 3).  
269 Before and 2 hours after injection of L-NPA and during flicker stimulation, the systemic

270 parameters (pH, PaCO<sub>2</sub>, PaO<sub>2</sub>, HCO<sub>3</sub><sup>-</sup>, MABP, or HR) did not change significantly  
271 (data not shown).

### 272 **Histologic Examination**

273 Fig. 4 shows transverse retinal sections stained with HE. There were no apparent  
274 changes in morphology in the GCL, INL, or ONL in the LAA-treated eyes. A  
275 quantitative assessment of the effect of LAA on the GCL, INL, and ONL is shown in  
276 Table 4. There were no significant ( $P > 0.05$ ) differences in the thickness in each layer  
277 between the LAA-treated and control eyes.

### 278 **Immunohistochemistry**

279 To examine the effect of LAA, GFAP staining was assessed in the whole retina (Fig. 5).  
280 GFAP immunofluorescence histochemistry (green astrocytes) and binding of isolectin  
281 IB4 (red vessels) was performed on flat-mounted feline retinal preparations before (Fig.  
282 5A) and 24 hours after intravitreal injection of 60 mM of LAA (Fig. 5B). Compared  
283 with the control, mean densities of GFAP expression were significantly ( $P < 0.05$ )  
284 reduced in LAA-treated eyes (Table 5).

285

### 286 **DISCUSSION**

287 Many studies have reported that glial cells contribute to neurovascular coupling in the  
288 brain.<sup>30-35</sup> Metea and Newman reported that glial cells may contribute to neurovascular  
289 coupling in the rat ex vivo retina.<sup>6</sup> In that study, selective stimulation of glial cells  
290 resulted in both vasodilation and vasoconstriction, and light-evoked vasodilation was  
291 blocked when the purinergic antagonist suramin interrupted neuronal-to-glial signaling.<sup>6</sup>  
292 In the current study, though we did not observe decreases in the RBF, we showed that  
293 the increases in RBF during flicker stimulation were attenuated significantly by

294 intravitreal injection of LAA compared with the control (Fig. 2). These conflicting  
295 results may be due to differences in experimental methodology, i.e., the current study  
296 was an in vivo experiment in cats, whereas the previous report used ex vivo  
297 whole-mount rat retina. However, both studies clearly showed that retinal glial cells  
298 regulate RBF during flicker stimulation.

299       Although recent ex vivo animal studies have reported that the retinal glial cells  
300 may play a principal role in functional hyperemia,<sup>6,16</sup> it is unclear whether glial cells  
301 regulate basal blood flow in the in vivo retina. In the current study, there was no  
302 significant difference in the basal RBF between before and after intravitreal injection of  
303 LAA (Table 2). Although the current findings cannot fully answer the question, there are  
304 three plausible reasons for this result. First, glial cells do not help regulate basal blood  
305 flow in the retina; second, the retina has a compensatory mechanism for regulating basal  
306 blood flow after suppressed glial function; and third, the retinal glial cells are partially  
307 blocked by LAA at a concentration of 60 mM so that the basal RBF does not change.  
308 Further studies are needed to clarify whether retinal glial cells help regulate basal blood  
309 flow.

310       Previous studies have shown that NO plays an important role in flicker-induced  
311 vasodilation in animals<sup>4</sup> and humans.<sup>36</sup> Recently, we reported that L-NPA (5 mM), a  
312 selective nNOS inhibitor, reduced flicker-induced increases in RBF by a third of the  
313 baseline value in cats, meaning that two-thirds of the flicker-induced hyperemia is  
314 generated by NO by nNOS in neuronal and/or glial cells in the retina.<sup>26</sup> The current  
315 study confirmed that LAA (60 mM) as a gliotoxic compound reduced flicker-induced  
316 increases in the RBF by a third of the baseline value, indicating that two-thirds of the  
317 flicker-induced hyperemia is generated by the retinal glial cells. In addition, a

318 flicker-induced increase in RBF was abolished by double blocking with L-NPA (5 mM)  
319 and LAA (60 mM). These results suggested that flicker-induced hyperemia may be  
320 generated by three prominent vasodilatory factors: NO by the nNOS in neurons, NO by  
321 the nNOS in glial cells, and another vasodilatory factor in glial cells (Fig. 5). Indeed,  
322 some studies have reported that nNOS protein was expressed in neurons and glial cells  
323 in mammalian retina.<sup>37-42</sup> Moreover, in retinal functional hyperemia, there are several  
324 vasodilatory candidates in glial cells without NO from glial cells, such as prostaglandin  
325 E<sub>2</sub> (PGE<sub>2</sub>) and epoxyeicosatrienoic acids (EETs).<sup>32</sup> The current study did not confirm  
326 definitively that the retinal glial cells play a dominant role (at least accounting for  
327 two-thirds of the regulation in flicker-induced hyperemia) in regulating flicker-induced  
328 hyperemia in the retina. Further studies should determine the role of vasodilatory factors  
329 other than NO in glial cells in regulating flicker-induced hyperemia in the retina.

330 It is well known that pericytes cover a large fraction of the capillary surface in the  
331 brain. Vasoactive molecules such as NO, PGE<sub>2</sub>, or EETs in astrocytes may cause  
332 pericytic dilation in capillaries and increase cerebral blood flow in functional  
333 hyperemia.<sup>43</sup> In the retina, pericytes cover the capillary surface more extensively than in  
334 the brain,<sup>44</sup> indicating that the interaction between glial cells and pericytes may be more  
335 important in functional hyperemia in the retina than the brain. Moreover, Kornfield and  
336 Newman reported that flicker-evoked vasodilation depended on vessel size and depth in  
337 the retina.<sup>45</sup> Indeed, both pericytic loss and impaired glial activity in the retina are  
338 detected before DR appears clinically and then the diminished response in  
339 flicker-evoked vasodilation is observed.<sup>46,47</sup> In the current study, suppression of the  
340 flicker-evoked increase in blood V was greater compared with that in vessel D in  
341 LAA-treated eyes. Because blood V in the retinal arterioles measured by LDV may



342 reflect the entire hemodynamics in the retinal vasculature including the downstream  
343 arterioles and capillaries, the current findings suggested that capillaries and not retinal  
344 arterioles may be primarily responsible for controlling the retinal circulation in  
345 flicker-induced hyperemia in the retina, which was mediated by glial cell activity.

346 In the present study, there were no significant changes in the implicit time of the  
347 ERG a- and b-waves after intravitreal injection of LAA at a concentration of 60 mM  
348 (Table 3). Although Welinder et al. reported that the amplitude of the ERG b-wave  
349 decreased in rabbit eyes injected with LAA<sup>48</sup>, they used a high concentration of LAA  
350 (150 mM) greater than in our study. Indeed, another previous report showed that LAA  
351 at a concentration of 200 mM caused neural damage and significant affected the ERG  
352 b-wave at 24 hours in rabbits.<sup>17</sup> In our preliminary experiment, we also confirmed that  
353 LAA at a concentration of 200 mM caused a significant reduction in the amplitude of  
354 the ERG b-wave in cats (data not shown). However, some reports have suggested that  
355 the implicit time of the ERG b-wave was not prolonged significantly after injections of  
356 low concentrations of LAA despite changes in the Muller cells and astrocytes.<sup>19,20</sup> In  
357 fact, a recent immunohistochemistry evaluation found that LAA at a concentration of 60  
358 mM damaged the retinal glial cells, histologic evaluation showed intact neural cells, and  
359 there were no significant reduction of the ERG b-wave.<sup>17</sup> In addition, we also  
360 determined whether 60 mM of LAA injected intravitreally may have any toxic effects  
361 on the neurons, which was confirmed by ERG and histologic examination in the current  
362 study. Despite the morphologic changes in the glial cells after LAA (Fig. 5, Table 5), the  
363 implicit time and amplitudes of the ERG a- and b-waves (Table 3) and the thickness of  
364 the GCL, INL, and ONL (Table 4) did not change significantly after intravitreal  
365 injection of a 60-mM concentration of LAA compared with the control. In addition, the

366 increase in RBF induced by BK, which elicits endothelium-dependent, NO-mediated  
367 vasodilation in isolated porcine retinal arterioles,<sup>28</sup> did not change significantly after  
368 intravitreal injection of both concentrations of LAA (Fig. 1). These results suggested  
369 that LAA concentrations in the current study selectively damaged glial cells without  
370 hurting the neurons and retinal vasculature.

371       The current study had some limitations. First, we did not clarify the detailed  
372 molecular mechanism of how retinal glial cells regulate RBF in response to flicker  
373 stimulation. Although we recently found possible involvement of the retinal NO derived  
374 from nNOS in flicker-induced hyperemia in the retina in anesthetized cats,<sup>26</sup> the current  
375 findings that L-NPA further reduced flicker-induced hyperemia in the retina after LAA  
376 treatment may indicate that NO derived from nNOS in retinal neurons and retinal glial  
377 cells may be involved in the flicker-induced hyperemia in the retina. In addition,  
378 although it was suggested that one particular mechanism of neurovascular coupling in  
379 which glial cells release vasodilatory PGE<sub>2</sub> and/or EETs as the arachidonic acid  
380 metabolites produced by cyclooxygenase (COX) is a principal and perhaps dominant  
381 mechanism mediating functional hyperemia in the retina,<sup>5</sup> we did not examine the role  
382 of these molecules in flicker-induced hyperemia in the retina because there is no  
383 selective and specific blocker of COX that is only in the retinal glial cells. Second, the  
384 current results did not determine which retinal glial cells, the Müller glial cells or  
385 astrocytes, play a central role in retinal circulation in response to flicker stimulation,  
386 because it is difficult to suppress separately each cellular function using a gliotoxic  
387 compound, which affects both of them.<sup>19,20</sup> Third, although the current data did not  
388 provide a definitive explanation for the effect of general anesthesia, we previously  
389 found in a preliminary study that sevoflurane per se did not change the vessel D of

390 isolated porcine retinal arterioles (data not shown) and the changes in the concentration  
391 of pancuronium bromide did not alter the RBF in cats anesthetized with sevoflurane  
392 (data not shown).<sup>26</sup> Finally, we could not investigate to what degree the retinal glial  
393 cells contributed to the basal RBF, because it is difficult to quantify the degree of  
394 functional damages in the retinal glial cells after intravitreal injection of LAA at a  
395 concentration of 60 mM. To resolve this issue, more advanced techniques and research  
396 are needed in the future.

397       Impaired glial cellular activity is related to the pathogenesis of some ocular  
398 diseases, such as DR or glaucoma.<sup>9-12</sup> In addition, these ocular diseases also have  
399 impaired regulation of ocular blood flow and decreases in flicker-evoked retinal  
400 vasodilation.<sup>15,47,49,50</sup> Although it is unclear whether glial cell dysfunction or  
401 insufficiency of the retinal circulation is the initial pathogenetic event in these diseases,  
402 dysfunction of the retinal glial cells participates in progression in these diseases.  
403 Therefore, further basic and clinical studies are warranted to examine whether improved  
404 glial function may be a novel target for treating ocular vascular disorders.

405       In conclusion, we found for the first time that the flicker-induced hyperemia in the  
406 retina was decreased in LAA-treated eyes, suggesting that glial cells play a major role in  
407 regulating RBF in response to flicker stimulation. Our findings indicated that three  
408 prominent types of vasodilators, i.e., nNOS from neurons, nNOS from glial cells, and  
409 other vasodilatory factors from glia, may contribute to the phenomena (Fig. 5). Because  
410 it has been reported previously that glial cell dysfunction may be involved in the  
411 pathogenesis of DR and glaucoma,<sup>9-12</sup> clarifying the detailed mechanisms of glial cells  
412 in the retinal vasculature may provide a further understanding of the pathogenesis in  
413 these ocular disorders.

414 **References**

- 415 1. Roy CS, Sherrington CS. On the Regulation of the Blood-supply of the Brain. *J*  
416 *Physiol.* 1890;11:85-158 117.
- 417 2. Attwell D, Buchan AM, Charpak S, Lauritzen M, Macvicar BA, Newman EA.  
418 Glial and neuronal control of brain blood flow. *Nature.* 2010;468:232-243.
- 419 3. Riva CE, Logean E, Falsini B. Visually evoked hemodynamical response and  
420 assessment of neurovascular coupling in the optic nerve and retina. *Prog Retin Eye*  
421 *Res.* 2005;24:183-215.
- 422 4. Kondo M, Wang L, Bill A. The role of nitric oxide in hyperaemic response to  
423 flicker in the retina and optic nerve in cats. *Acta Ophthalmol Scand*  
424 1997;75:232-235.
- 425 5. Newman EA. Functional hyperemia and mechanisms of neurovascular coupling in  
426 the retinal vasculature. *J Cereb Blood Flow Metab.* 2013;33:1685-1695.
- 427 6. Metea MR, Newman EA. Glial cells dilate and constrict blood vessels: a  
428 mechanism of neurovascular coupling. *J Neurosci.* 2006;26:2862-2870.
- 429 7. Hernandez MR. The optic nerve head in glaucoma: role of astrocytes in tissue  
430 remodeling. *Prog Retin Eye Res.* 2000;19:297-321.

- 431 8. Bringmann A, Pannicke T, Grosche J, et al. Muller cells in the healthy and  
432 diseased retina. *Prog Retin Eye Res.* 2006;25:397-424.
- 433 9. Weinreb RN, Khaw PT. Primary open-angle glaucoma. *Lancet.*  
434 2004;363:1711-1720.
- 435 10. Lieth E, Barber AJ, Xu B, et al. Glial reactivity and impaired glutamate  
436 metabolism in short-term experimental diabetic retinopathy. Penn State Retina  
437 Research Group. *Diabetes.* 1998;47:815-820.
- 438 11. Chihara E, Matsuoka T, Ogura Y, Matsumura M. Retinal nerve fiber layer defect  
439 as an early manifestation of diabetic retinopathy. *Ophthalmology.*  
440 1993;100:1147-1151.
- 441 12. Bloodworth JM, Jr. Diabetic retinopathy. *Diabetes.* 1962;11:1-22.
- 442 13. Lasta M, Pemp B, Schmidl D, et al. Neurovascular dysfunction precedes neural  
443 dysfunction in the retina of patients with type 1 diabetes. *Invest Ophthalmol Vis*  
444 *Sci.* 2013;54:842-847.
- 445 14. Nguyen TT, Shaw JE, Robinson C, et al. Diabetic retinopathy is related to both  
446 endothelium-dependent and -independent responses of skin microvascular flow.

- 447        *Diabetes Care*. 2011;34:1389-1393.
- 448    15.    Garhofer G, Zawinka C, Resch H, Huemer KH, Schmetterer L, Dorner GT.  
449        Response of retinal vessel diameters to flicker stimulation in patients with early  
450        open angle glaucoma. *J Glaucoma*. 2004;13:340-344.
- 451    16.    Newman EA. Calcium increases in retinal glial cells evoked by light-induced  
452        neuronal activity. *J Neurosci*. 2005;25:5502-5510.
- 453    17.    Shibata M, Sugiyama T, Kurimoto T, et al. Involvement of glial cells in the  
454        autoregulation of optic nerve head blood flow in rabbits. *Invest Ophthalmol Vis  
455        Sci*. 2012;53:3726-3732.
- 456    18.    Mishra A, Hamid A, Newman EA. Oxygen modulation of neurovascular coupling  
457        in the retina. *Proc Natl Acad Sci U S A*. 2011;108:17827-17831.
- 458    19.    Bonaventure N, Roussel G, Wioland N. Effects of DL-alpha-amino adipic acid on  
459        Muller cells in frog and chicken retinae in vivo: relation to ERG b wave, ganglion  
460        cell discharge and tectal evoked potentials. *Neurosci Lett*. 1981;27:81-87.
- 461    20.    Pedersen OO, Karlsen RL. Destruction of Muller cells in the adult rat by  
462        intravitreal injection of D,L-alpha-amino adipic acid. An electron microscopic

- 463 study. *ExperEye Res.* 1979;28:569-575.
- 464 21. Nagaoka T, Sakamoto T, Mori F, Sato E, Yoshida A. The effect of nitric oxide on  
465 retinal blood flow during hypoxia in cats. *Invest Ophthalmol Vis. Sci.*  
466 2002;43:3037-3044.
- 467 22. Yoshida A, Feke GT, Mori F, et al. Reproducibility and clinical application of a  
468 newly developed stabilized retinal laser Doppler instrument. *Am J Ophthalmol*  
469 2003;135:356-361.
- 470 23. Feke GT, Goger DG, Tagawa H, Delori FC. Laser Doppler technique for absolute  
471 measurement of blood speed in retinal vessels. *IEEE T Bio Med Eng.*  
472 1987;34:673-680.
- 473 24. Nakabayashi S, Nagaoka T, Tani T, et al. Retinal arteriolar responses to acute  
474 severe elevation in systemic blood pressure in cats: role of endothelium-derived  
475 factors. *Exper Eye Res.* 2012;103:63-70.
- 476 25. Riva CE, Cranstoun SD, Mann RM, Barnes GE. Local choroidal blood flow in the  
477 cat by laser Doppler flowmetry. *Invest Ophthalmol Vis. Sci.* 1994;35:608-618.
- 478 26. Yoshioka T, Nagaoka T, Song Y, Yokota H, Tani T, Yoshida A. Role of neuronal

- 479 nitric oxide synthase in regulating retinal blood flow during flicker-induced  
480 hyperemia in cats. *Invest Ophthalmol Vis. Sci.* 2015;56(5):3113-20.
- 481 27. Ishikawa Y, Mine S. Aminoadipic acid toxic effects on retinal glial cells. *Jpn J*  
482 *Ophthalmol.* 1983;27:107-118.
- 483 28. Nagaoka T, Kuo L, Ren Y, Yoshida A, Hein TW. C-reactive protein inhibits  
484 endothelium-dependent nitric oxide-mediated dilation of retinal arterioles via  
485 enhanced superoxide production. *Invest Ophthalmol Vis. Sci.* 2008;49:2053-2060.
- 486 29. Sogawa K, Nagaoka T, Izumi N, Nakabayashi S, Yoshida A. Acute  
487 hyperglycemia-induced endothelial dysfunction in retinal arterioles in cats. *Invest*  
488 *Ophthalmol Vis. Sci.* 2010;51:2648-2655.
- 489 30. Koehler RC, Gebremedhin D, Harder DR. Role of astrocytes in cerebrovascular  
490 regulation. *J Appl Physiol.* 2006;100:307-317.
- 491 31. Zonta M, Angulo MC, Gobbo S, et al. Neuron-to-astrocyte signaling is central to  
492 the dynamic control of brain microcirculation. *Nature Neurosci.* 2003;6:43-50.
- 493 32. Harder DR, Alkayed NJ, Lange AR, Gebremedhin D, Roman RJ. Functional  
494 hyperemia in the brain: hypothesis for astrocyte-derived vasodilator metabolites.



- 495        *Stroke*. 1998;29:229-234.
- 496    33. Paulson OB, Newman EA. Does the release of potassium from astrocyte endfeet  
497        regulate cerebral blood flow? *Science*. 1987;237:896-898.
- 498    34. Mulligan SJ, MacVicar BA. Calcium transients in astrocyte endfeet cause  
499        cerebrovascular constrictions. *Nature*. 2004;431:195-199.
- 500    35. Filosa JA, Bonev AD, Nelson MT. Calcium dynamics in cortical astrocytes and  
501        arterioles during neurovascular coupling. *Circulation Res*. 2004;95:e73-81.
- 502    36. Dorner GT, Garhofer G, Kiss B, et al. Nitric oxide regulates retinal vascular tone  
503        in humans. *Am J Physiol Heart Circ Physiol*. 2003;285:H631-636.
- 504    37. Koch KW, Lambrecht HG, Haberecht M, Redburn D, Schmidt HH. Functional  
505        coupling of a Ca<sup>2+</sup>/calmodulin-dependent nitric oxide synthase and a soluble  
506        guanylyl cyclase in vertebrate photoreceptor cells. *EMBO J*. 1994;13:3312-3320.
- 507    38. Goureau O, Hicks D, Courtois Y, De Kozak Y. Induction and regulation of nitric  
508        oxide synthase in retinal Muller glial cells. *J Neurochem*, 1994;63:310-317.
- 509    39. Yamamoto R, Bredt DS, Snyder SH, Stone RA. The localization of nitric oxide  
510        synthase in the rat eye and related cranial ganglia. *Neuroscience*.

- 511 1993;54:189-200.
- 512 40. Osborne NN, Barnett NL, Herrera AJ. NADPH diaphorase localization and nitric  
513 oxide synthetase activity in the retina and anterior uvea of the rabbit eye. *Brain*  
514 *Res.* 1993;610:194-198.
- 515 41. Venturini CM, Knowles RG, Palmer RM, Moncada S. Synthesis of nitric oxide in  
516 the bovine retina. *Biochem Biophys Res Comm.* 1991;180:920-925.
- 517 42. Dawson TM, Brecht DS, Fotuhi M, Hwang PM, Snyder SH. Nitric oxide synthase  
518 and neuronal NADPH diaphorase are identical in brain and peripheral tissues.  
519 *Proceedings of the Natlional Academy of Sciences of the United States of America*  
520 *U S A.* 1991;88:7797-7801.
- 521 43. Hall CN, Reynell C, Gesslein B, et al. Capillary pericytes regulate cerebral blood  
522 flow in health and disease. *Nature.* 2014;508:55-60.
- 523 44. Frank RN, Dutta S, Mancini MA. Pericyte coverage is greater in the retinal than in  
524 the cerebral capillaries of the rat. *Invest Ophthalmol Vis Sci.* 1987;28:1086-1091.
- 525 45. Kornfield TE, Newman EA. Regulation of blood flow in the retinal trilaminar  
526 vascular network. *J Neurosci.* 2014;34:11504-11513.

- 527 46. Barber AJ, Gardner TW, Abcouwer SF. The significance of vascular and neural  
528 apoptosis to the pathology of diabetic retinopathy. *Invest Ophthalmol Vis Sci*.  
529 2011;52:1156-1163.
- 530 47. Nguyen TT, Kawasaki R, Wang JJ, et al. Flicker light-induced retinal vasodilation  
531 in diabetes and diabetic retinopathy. *Diabetes Care*. 2009;32:2075-2080.
- 532 48. Welinder E, Textorius O, Nilsson SE. Effects of intravitreally injected  
533 DL-alpha-aminoadipic acid on the c-wave of the D.C.-recorded electroretinogram  
534 in albino rabbits. *Invest Ophthalmol Vis Sci*. 1982;23:240-245.
- 535 49. Moore D, Harris A, Wudunn D, Kheradiya N, Siesky B. Dysfunctional regulation  
536 of ocular blood flow: A risk factor for glaucoma? *Clin Ophthalmol*.  
537 2008;2:849-861.
- 538 50. Kohner EM, Patel V, Rassam SM. Role of blood flow and impaired autoregulation  
539 in the pathogenesis of diabetic retinopathy. *Diabetes*. 1995;44:603-607.  
540  
541  
542  
543  
544

545 **Legends**

546 **FIGURE 1.** Effect of LAA on the vasodilatory response to bradykinin. Three groups  
547 include five subjects each. The data are expressed as the mean percentage  $\pm$  standard  
548 error of the mean of the pre-injection levels. We used two-way factorial ANOVA  
549 followed by the Dunnett procedure to compare LAA (20 and 60 mM) with the control  
550 group.  $P < 0.05$  is considered statistically significant. There are no significant  
551 differences among the three groups. N.S., not significant; D, diameter; V, velocity; F,  
552 retinal blood flow.

553

554 **FIGURE 2.** Time course of the changes from baseline in retinal circulation in response to  
555 flicker stimulation in the following groups: 0.01N HCl (n=6) as a control, 20 mM of  
556 LAA (n=6), and 60 mM of LAA (n=6). (A) The black bar represents the period of  
557 flicker (3 minutes) (frequency 16 Hz, modulation depth 100%, dark adaptation time 2  
558 hours). The data are expressed as the mean percentage  $\pm$  standard error of the mean of  
559 baseline.  $*P < 0.05$  and  $^{\dagger}P < 0.05$  compared with a control group by two-way  
560 repeated-measures ANOVA followed by the Dunnett procedure. (B) Maximal changes  
561 from baseline in the retinal circulation in response to flicker stimulation in A. The data  
562 are expressed as the mean percentage  $\pm$  standard error of the mean of baseline.  $*P <$   
563  $0.05$  compared with a control group by one-way factorial ANOVA followed by the  
564 Dunnett procedure. D, diameter; V, velocity; F, retinal blood flow.

565

566 **Figure 3.** Effect of L-NPA (nNOS) inhibitor) on the flicker-evoked increase in retinal  
567 circulation in LAA-treated eyes. The data are expressed as the mean percentage  $\pm$   
568 standard error of the mean of baseline.  $*P < 0.05$  is considered significant. We used the

569 two-way factorial ANOVA followed by the Dunnett procedure to compare between  
570 before and 2 hours after intravitreal injection of L-NPA in eyes treated with 60 mM of  
571 LAA. Flicker-evoked increases in the retinal circulation 2 hours after intravitreal  
572 injection of L-NPA (5 mM) in eyes treated with 60 mM of LAA have decreased  
573 significantly compared with eyes treated with only 60 mM of LAA.

574

575 **Figure 4.** Photomicrographs of transverse sections of the retina stained with  
576 hematoxylin and eosin (HE). Each section was obtained from eyes with intravitreal  
577 injection of 0.01 N HCl as a control (A) and LAA at 60 mM. No apparent changes are  
578 observed in the ganglion cell layer (GCL), inner nuclear cell layer (INL), and outer  
579 nuclear layer (ONL) of the retina. Black bar = 50  $\mu$ m.

580

581 **Figure 5.** Immunohistochemistry of flat-mounted retina. Astrocytes are stained with  
582 anti- GFAP antibody (green) and vessels are stained with lectin IB4 (red). The retinas  
583 were dissected from eyes given an intravitreal injection of 0.01N HCl as a control (A)  
584 and LAA at a concentration of 60 mM (B). Compared with the control (A), the  
585 astrocytic processes in LAA-treated eyes (B) seem shorter and deformed. White bar =  
586 50  $\mu$ m.

587

588 **Figure 6.** Scheme of the mechanisms of flicker-induced hyperemia in the retina.  
589 Putative mechanisms of the flicker-induced hyperemia in the retina. Three prominent  
590 types of vasodilators may contribute to the phenomena.

591

592

593 **Tables**594 **Table 1.** Systemic and Ocular Parameters at Rest

	<b>Control</b> <b>(n=6)</b>	<b>LAA 20 mM</b> <b>(n=6)</b>	<b>LAA 60 mM</b> <b>(n=6)</b>
pH	7.42 ± 0.01	7.42 ± 0.01	7.43 ± 0.01
PaCO <sub>2</sub> , mmHg	27.2 ± 1.1	26.1 ± 0.8	26.7 ± 0.2
PaO <sub>2</sub> , mmHg	140.3 ± 5.9	140.8 ± 4.9	139.6 ± 0.7
HCO <sub>3</sub> <sup>-</sup> , mmol/l	17.0 ± 0.5	16.8 ± 0.4	16.6 ± 0.1
MABP, mmHg	129.0 ± 2.7	127.1 ± 2.2	128.0 ± 0.7
HR, beats/min	145.0 ± 4.7	149.6 ± 3.9	142.3 ± 3.1
OPP, mmHg	114.0 ± 2.7	112.1 ± 2.2	114.9 ± 2.6
Diameter, μm	114.3 ± 2.2	116.0 ± 2.4	117.0 ± 1.5
Velocity, mm/sec	32.3 ± 2.1	30.2 ± 3.4	29.3 ± 2.4
RBF, μL/min	9.9 ± 0.3	9.6 ± 1.0	9.6 ± 0.9

595

596 Control means 0.01 N HCl as a solvent of LAA. Data are expressed as the mean ±  
597 standard error of the mean. We used the Mann-Whitney U-test to compare the control  
598 group with LAA groups (20 and 60 mM). *P* < 0.05 is considered significant. There are  
599 no significant differences between the groups.

600

601 **Table 2.** Systemic and Ocular Parameters Before and 24 Hours after Intravitreal  
 602 Injection of LAA at 60 mM (n=4)

	Before	After
pH	7.42 ± 0.01	7.40 ± 0.01
PaCO <sub>2</sub> , mmHg	27.2 ± 1.1	28.6 ± 1.0
PaO <sub>2</sub> , mmHg	114.3 ± 2.6	111.8 ± 4.1
HCO <sub>3</sub> <sup>-</sup> , mmol/l	20.7 ± 0.7	20.1 ± 0.3
MABP, mmHg	103.2 ± 1.0	101.3 ± 1.3
HR, beats/min	121.0 ± 1.4	120.3 ± 4.3
OPP, mmHg	93.6 ± 0.9	91.7 ± 1.4
Diameter, μm	110.6 ± 2.9	110.7 ± 4.0
Velocity, mm/sec	31.1 ± 3.6	34.6 ± 2.9
RBF, μL/min	9.0 ± 1.3	10.2 ± 1.4

603

604 The data are the actual measured values. Each data point (before and after) was  
 605 measured in the same individual. Data are expressed as the means ± standard error of  
 606 the mean. To compare before with after injections of LAA (60 mM), we used the  
 607 Wilcoxon signed-rank test.  $P < 0.05$  is considered significant. There are no significant  
 608 ( $P > 0.05$ ) differences in any parameters between before and after injections. Before  
 609 indicates before the intravitreal injections; after indicates 24 hours after the intravitreal  
 610 injections.

611

612 **Table 3.** Effect of LAA on ERGs (n=7)

	Control	LAA (60 mM)	P Values
a-wave			
%Amplitude	103.2 ± 4.6	99.0 ± 5.2	0.38
%Implicit time	102.5 ± 4.2	99.6 ± 4.4	0.74
b-wave			
%Amplitude	96.0 ± 5.0	105.1 ± 6.5	0.52
%Implicit time	100.3 ± 3.1	101.9 ± 3.6	0.45

613

614 Data are expressed as the means ± standard error of the mean of values relative to the

615 baseline for 7 cats each. *P* values obtained using the Mann-Whitney U-test are shown.616 There are no significant ( $P > 0.05$ ) differences in any parameters between the groups.

617

618

619

620

621

622

623

624

625

626

627



628 **Table 4.** Thicknesses of the GCL,INL, and ONL before and 24 Hours after Intravitreal  
 629 Injection of LAA (60 mM) (n=5)

	<b>Control</b>	<b>LAA 60 mM</b>	<b><i>P</i> Value</b>
GCL ( $\mu\text{m}$ )	16.1 $\pm$ 0.8	15.9 $\pm$ 0.9	0.59
INL ( $\mu\text{m}$ )	17.8 $\pm$ 0.5	19.4 $\pm$ 0.7	0.16
ONL ( $\mu\text{m}$ )	46.6 $\pm$ 2.2	50.7 $\pm$ 3.0	0.28

630  
 631 Data are expressed as the mean  $\pm$  standard error of the mean for 5 cats. *P* values obtained  
 632 by Mann-Whitney U-test are shown. There are no significant differences ( $P > 0.05$ ) in  
 633 any layers between groups.

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649 **Table 5. Mean Densities (pixels/mm) of GFAP Expression in the Retina**

	<b>Control</b>	<b>LAA 60 mM</b>	<b><i>P</i> Value</b>
Mean density, pixels/mm	184305.5 ± 26600.2	27675.6 ± 3190.5	0.03

650

651 The mean densities of GFAP expression in astrocytes were compared quantitatively  
652 between two groups. Compared with the control, the mean densities of GFAP  
653 expression are significantly ( $P = 0.03$ ) reduced in LAA-treated eyes analyzed using the  
654 Mann-Whitney U-test. Data are expressed as mean ± standard error of the mean in two  
655 groups.

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678 **Supplemental Tables**679 **Supplemental Table 1.** Effect of BK on Systemic Parameters in Figure 2 (n=5)

	<b>Before</b>	<b>120 min</b>
pH	7.40 ± 0.02	7.41 ± 0.01
PaCO <sub>2</sub> , mmHg	27.9 ± 1.8	29.6 ± 1.5
PaO <sub>2</sub> , mmHg	107.4 ± 4.2	110.0 ± 3.8
HCO <sub>3</sub> <sup>-</sup> , mmol/l	17.3 ± 0.3	17.5 ± 0.5
MABP, mmHg	114.5 ± 5.0	111.4 ± 4.8
HR, beats/min	133.7 ± 5.1	132.0 ± 3.5
OPP, mmHg	101.5 ± 2.2	99.3 ± 2.6

680

681 Data are expressed as the mean ± standard error of the mean. Before indicates before the  
682 intravitreal injections; 120 minutes indicates 120 minutes after the intravitreal injections.  
683 The number of animals is 5 in each group. There are no significant ( $P = 0.05$ ) differences  
684 in all parameters between before and 120 minutes after injections.

685

686

687

688

689

690

691

692

693

694

695 **Supplemental Table 2.** Effect of L-NPA on systemic Parameters in Figure 3 (n=5)

	<b>Before</b>	<b>120 min</b>
pH	7.41 ± 0.01	7.43 ± 0.01
PaCO <sub>2</sub> , mmHg	26.5 ± 1.4	26.4 ± 1.7
PaO <sub>2</sub> , mmHg	108.4 ± 3.1	108.4 ± 3.8
HCO <sub>3</sub> <sup>-</sup> , mmol/l	16.5 ± 0.3	16.4 ± 0.4
MABP, mmHg	108.2 ± 3.6	108.6 ± 4.7
HR, beats/min	131.0 ± 4.7	131.0 ± 5.0
OPP, mmHg	98.1 ± 2.6	98.5 ± 2.7

696

697 Data are expressed as the mean ± standard error of the mean. Before indicates before the  
 698 intravitreal injections; 120 minutes indicates 120 minutes after the intravitreal injections.

699 The number of animals is 5 in each group. There are no significant ( $P = 0.05$ ) differences  
 700 in all parameters between before and 120 minutes after injections.

701

702

703

704

705

706

707

708


709

710

711


712 **Figures**

**Figure 1.**




713

**Figure 2A.**




**Figure 2B.**




714

**Figure 3.**




715

Figure 4.




716

Figure 5.



717

Figure 6.



718